Effect of Time to Titration to Maximum Dose of Statins on Cardiovascular Outcomes

[1]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[2]  E. Braunwald,et al.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[3]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[4]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[5]  H. Silbershatz,et al.  Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. , 2003, The American journal of cardiology.

[6]  K. Bybee,et al.  Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. , 2002, Mayo Clinic proceedings.

[7]  Kathleen M. Weil,et al.  Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction , 2002, Circulation.

[8]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[9]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .